Exenatide

Exenatide is a synthetic copy of exendin-4, a 39-amino-acid peptide first isolated from the saliva of the Gila monster lizard. Despite sharing only 53% of its sequence with human GLP-1, it fully activates the human GLP-1 receptor and, unlike the natural hormone, resists breakdown by the enzyme DPP-4 — which is why it works as a drug while GLP-1 itself does not. It was the first GLP-1 receptor agonist approved by the FDA, in 2005 as Byetta.

Both exenatide formulations — the twice-daily Byetta and the once-weekly Bydureon BCise — were withdrawn from the US market in October 2024. The reason isn't documented here; what is documented is that newer GLP-1 drugs had already displaced it clinically by then, since exenatide produces smaller HbA1c reductions (0.8-1.5%) than the newer agents and, unlike them, was never approved for weight loss despite nearly two decades on the market.

In pooled trials — six randomized studies, 362 adults without diabetes, 12 to 24 weeks — people on exenatide lost about 4.5 kg more than those on placebo, and that effect held across whatever dose was used, since no obesity-specific dose was ever established. Despite this signal, exenatide's manufacturer never filed for a weight-loss indication in two decades, and no trial has followed people on it for longer than six months.

An earlier phase 2 trial found that once-weekly exenatide improved OFF-state motor scores in people with Parkinson's disease, suggesting a possible disease-modifying effect. The follow-up phase 3 trial did not confirm this: over 96 weeks, motor scores actually worsened more on exenatide than on placebo, and a Lancet Expression of Concern has since been issued regarding that phase 3 publication. Current evidence does not support a Parkinson's benefit.

Digestive effects dominate, especially with the twice-daily form: nausea in about 44% of users, vomiting in 13%, and diarrhea in 13%. The once-weekly extended-release version causes less nausea because the drug releases more gradually, but it can cause small nodules at the injection site from the microsphere particles. Pancreatitis is a rare but recognized risk, there is a thyroid C-cell tumor warning based on rodent data, and some patients develop antibodies against the drug.

Exenatide binds the GLP-1 receptor on pancreatic beta cells, raising cyclic AMP through two branches — one via PKA, one via the protein Epac2 — that together amplify insulin release, but only once blood glucose has already started falling. A human clamp study found insulin secretion dropped rapidly once glucose fell below about 4 mmol/L, similarly to placebo, which is part of why it doesn't typically cause hypoglycemia on its own. It also slows stomach emptying and acts on appetite circuits in the brain.

Unopened, both Byetta pens and Bydureon extended-release kits are kept refrigerated at 2-8 °C and protected from light. Once a Byetta pen is in use, it can be kept at room temperature for up to 30 days; the Bydureon microsphere kit has no equivalent room-temperature allowance described, so it stays refrigerated throughout use, still protected from light.